Why a specific set of brain cells become vulnerable in Alzheimer’s

Metabolic Mechanisms in Locus Coeruleus Neuron Vulnerability in Neurodegenerative Disease

['FUNDING_R01'] · BROWN UNIVERSITY · NIH-11308279

This project looks at whether metabolic problems in a small group of brain cells cause early damage in people with Alzheimer’s and related diseases.

Quick facts

Phase['FUNDING_R01']
Study typeNih_funding
SexAll
SponsorBROWN UNIVERSITY (nih funded)
Locations1 site (PROVIDENCE, UNITED STATES)
Trial IDNIH-11308279 on ClinicalTrials.gov

What this research studies

Researchers will use mouse models that mimic Alzheimer’s and related conditions to study why the locus coeruleus — a small but important group of brain cells — breaks down early in the disease. They focus on a mitochondrial enzyme called GPT2 because mice lacking this enzyme show very early loss of these cells. The team will compare Gpt2-null mice with other Alzheimer’s and Down Syndrome models across different ages and perform gene-by-environment experiments to see what speeds vulnerability. The goal is to find metabolic steps that make these cells fragile so future therapies might protect them.

Who could benefit from this research

Good fit: People with Alzheimer’s disease, related dementias, or genetic risk factors for these conditions are the populations this research ultimately aims to help.

Not a fit: People looking for immediate treatments or those without neurodegenerative disease are unlikely to directly benefit from this preclinical, animal-based research.

Why it matters

Potential benefit: If successful, this work could identify metabolic targets to protect vulnerable brain cells early in Alzheimer’s and open new paths for treatments to slow disease progression.

How similar studies have performed: Previous studies have linked locus coeruleus loss and mitochondrial dysfunction to Alzheimer’s, but targeting GPT2 and its role in very early cell loss is a novel angle.

Where this research is happening

PROVIDENCE, UNITED STATES

Researchers

About this research

  1. This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
  2. Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
  3. For full project details, budget, and progress reports, visit the official NIH RePORTER page below.

View on NIH RePORTER →

Conditions: Alzheimer disease dementia, Alzheimer syndrome

Last reviewed 2026-05-15 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.